Rosetta Genomics and U.S. Genomics Announce Collaboration Agreement
Complete the form below to unlock access to ALL audio articles.
Rosetta Genomics Ltd. and U.S. Genomics Inc. have announced the signing of a discovery and co-development agreement for a microRNA-based, non-invasive early detection test for lung cancer.
This collaboration combines U.S. Genomics' patented Trilogy® 2020 platform and Direct™ miRNA assay with Rosetta Genomics' proprietary microRNAs.
By using Rosetta Genomics' microRNAs as biomarkers, together with U.S. Genomics' patented technology for sensitive molecular-level detection and quantitation, the two companies are working to create a molecular diagnostic test to accurately identify lung cancer using a sputum or blood sample.
"This alliance is intended to expedite the development of next-generation molecular diagnostic tests to identify cancer," said Amir Avniel, CEO and president of Rosetta Genomics.
"MicroRNAs hold great promise as biomarkers for several disease states, and we are very pleased to be working with U.S. Genomics to develop this new diagnostic tool for patients around the world."
"U.S. Genomics is excited about working with Rosetta Genomics to develop a microRNA-based diagnostic test for the early detection of lung cancer," said John Canepa, CEO and president of U.S. Genomics.
"Applying our Trilogy® 2020 single molecule detection platform and our Direct™ miRNA assays provide for best-in-class detection sensitivity of microRNAs without the inherent biases of amplification-based technologies."
"We are optimistic about combining these strengths with Rosetta Genomics' proprietary microRNAs to demonstrate the potential for a significantly more sensitive and accurate diagnostic test for this devastating disease."